Lenzetto (Estradiol)

Estradiol binds to estrogen receptors inside target cells, forming a complex that attaches to specific DNA sequences. This regulates the transcription of genes that control temperature regulation, bone remodeling, and the health of urogenital tissues, thereby compensating for the decline in natural estrogen after menopause.

The prescribed dose of Lenzetto is determined by the treating physician. The patch is designed to release 0.025 mg of estradiol over a 24‑hour period, and the clinician decides the frequency of patch changes based on individual therapeutic goals and response.

Safety data for Lenzetto in pregnancy are lacking, and estrogen therapy is generally contraindicated in known or suspected pregnancy. Limited information is available for breastfeeding; therefore, the product should be avoided unless the benefits clearly outweigh potential risks, as assessed by a healthcare professional.

To request Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenzetto delivers estradiol continuously through the skin, offering more stable plasma levels than oral formulations, which undergo first‑pass metabolism. Compared with other transdermal patches, its 0.025 mg/24 h dose is considered low‑to‑moderate, providing effective symptom control while potentially reducing the risk of systemic side effects.

Store Lenzetto at room temperature, below 25 °C, in its original pouch. Keep the patch away from direct sunlight, moisture and excessive heat. Do not fold or crush the patch, and discard any patch that appears damaged or discolored.

Lenzetto is applied to clean, dry, and hair‑free skin on the lower abdomen or upper buttock. The patch should be pressed firmly for at least 30 seconds to ensure good contact, and it is typically replaced every 24 hours, following the schedule set by the prescribing clinician.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, and stroke. Additional concerns are cardiovascular complications, liver dysfunction, and the potential stimulation of estrogen‑dependent cancers. Patients should be monitored closely for any signs of these conditions.

Lenzetto is contraindicated in women with known or suspected breast or endometrial cancer, active or past thromboembolic disease, uncontrolled hypertension, severe liver disease, and in anyone who is pregnant or planning pregnancy. It should also be avoided in individuals with known hypersensitivity to estradiol or any patch components.